Announcement

Collapse
No announcement yet.

J Virol . A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • J Virol . A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection


    J Virol


    . 2022 Aug 4;e0075822.
    doi: 10.1128/jvi.00758-22. Online ahead of print.
    A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection


    Rana Abdelnabi 1 , Caroline S Foo 1 , Suzanne J F Kaptein 1 , Robbert Boudewijns 1 , Laura Vangeel 1 , Steven De Jonghe 1 , Dirk Jochmans 1 2 3 , Birgit Weynand 4 , Johan Neyts 1 2 3



    Affiliations

    Abstract

    Ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lacks the intrinsic ability to bind to the mouse ACE2 receptor, and therefore establishment of SARS-CoV-2 mouse models has been limited to the use of mouse-adapted viruses or genetically modified mice. Interestingly, some of the variants of concern, such as the Beta B.1.351 variant, show an improved binding to the mouse receptor and hence better replication in different wild-type (WT) mouse species. Here, we describe the establishment of a SARS-CoV-2 Beta B.1.351 variant infection model in male SCID mice as a tool to assess the antiviral efficacy of potential SARS-CoV-2 small-molecule inhibitors. Intranasal infection of male SCID mice with 105 50% tissue culture infective doses (TCID50) of the Beta B.1.351 variant resulted in high viral loads in the lungs and moderate signs of lung pathology on day 3 postinfection. Treatment of infected mice with the antiviral drugs molnupiravir (200 mg/kg, twice a day [BID]) or nirmatrelvir (300 mg/kg, BID) for 3 consecutive days significantly reduced the infectious virus titers in the lungs by 2 and 3.9 log10 TCID50/mg of tissue, respectively, and significantly improved lung pathology. Together, these data demonstrate the validity of this SCID mouse Beta B.1.351 variant infection model as a convenient preclinical model for assessment of potential activity of antivirals against SARS-CoV-2. IMPORTANCE Unlike the ancestral SARS-CoV-2 strain, the Beta (B.1.351) variant of concern has been reported to replicate to some extent in WT mice (C57BL/6 and BALB/c). We demonstrate here that infection of SCID mice with the Beta variant resulted in high viral loads in the lungs on day 3 postinfection. Treatment of infected mice with molnupiravir or nirmatrelvir for 3 consecutive days markedly reduced the infectious virus titers in the lungs and improved lung pathology. The SARS-CoV2 SCID mouse infection model, which is ideally suited for antiviral studies, offers an advantage in comparison to other SARS-CoV2 mouse models, in that there is no need for the use of mouse-adapted virus strains or genetically modified mice. Mouse models also have advantages over hamster models because (i) lower amounts of test drugs are needed, (ii) more animals can be housed in a cage, and (iii) reagents to analyze mouse samples are more readily available than those for hamsters.

    Keywords: Beta variant; SARS-CoV-2; antivirals; molnupiravir; mouse model; nirmatrelvir.

Working...
X